TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Multifetal Gestation (STTARS)
Brief Summary: Women pregnant with twins or triplets are at high risk of preterm birth, yet no intervention or approach has served to reduce this risk. A recently completed trial by the NICHD sponsored Maternal Fetal Medicine Units (MFMU) Network has, for the first time, demonstrated a treatment that substantially reduces the rate of preterm birth in women at high risk for preterm delivery (i.e. progesterone therapy). Preterm birth was reduced by 35% among progesterone-treated women with a singleton pregnancy when compared with women receiving placebo. The current trial compares weekly treatment by injection of progesterone with placebo in women pregnant with twins or triplets.


Options:
A: Arm Label: 1 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone (OHP17) | Intervention Type: DRUG; Name: Progesterone (OHP17); Assigned to Arm(s): Progesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: 17 alpha-hydroxyprogesterone caproate (17P); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: 8% progesterone vaginal gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Vaginal Gel | Intervention Type: DRUG; Name: 8% progesterone vaginal gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Vaginal Gel; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Multifetal Gestation (STTARS)
Brief Summary: Women pregnant with twins or triplets are at high risk of preterm birth, yet no intervention or approach has served to reduce this risk. A recently completed trial by the NICHD sponsored Maternal Fetal Medicine Units (MFMU) Network has, for the first time, demonstrated a treatment that substantially reduces the rate of preterm birth in women at high risk for preterm delivery (i.e. progesterone therapy). Preterm birth was reduced by 35% among progesterone-treated women with a singleton pregnancy when compared with women receiving placebo. The current trial compares weekly treatment by injection of progesterone with placebo in women pregnant with twins or triplets.


Options:
A: Arm Label: 1 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone (OHP17) | Intervention Type: DRUG; Name: Progesterone (OHP17); Assigned to Arm(s): Progesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 Placebo
B: Arm Label: 17-alpha hydroxyprogesterone caproate, Makena®; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17-alpha-hydroxy-progesterone caproate, Makena® | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Castor Oil (Placebo) | Intervention Type: DRUG; Name: 17-alpha-hydroxy-progesterone caproate, Makena®; Assigned to Arm(s): 17-alpha hydroxyprogesterone caproate, Makena® | Intervention Type: DRUG; Name: Castor Oil (Placebo); Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: 17 alpha-hydroxyprogesterone caproate (17P); Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-term Effectiveness of Abdominal Sacrocolpopexy for the Treatment of Pelvic Organ Prolapse: The Extended Colpopexy and Urinary Reduction Efforts (E-CARE) Study
Brief Summary: The Colpopexy and Urinary Reduction Effort (CARE) trial is a research study designed to evaluate whether the addition of a second surgical procedure in addition to a procedure for female pelvic organ prolapse (POP) affects the rates of urinary incontinence. This study will follow women in the CARE study for 10 years from the time of the surgery to compare success and complication rates in the two groups. Recruitment into this study is open only to women that already participated in CARE. Recruitment into CARE is closed.


Options:
A: Intervention Type: PROCEDURE; Name: sacral colpopexy; Assigned to Arm(s): N/A
B: Arm Label: Abdominal Sacral Colpopexy with no Burch colposuspension; Type: N/A; Interventions: N/A | Arm Label: Abdominal Sacral Colpopexy with Burch Colposuspension; Type: N/A; Interventions: N/A
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: robotic laparoscopic sacrocolpopexy | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laparoscopic Sacral Colpopexy | Intervention Type: PROCEDURE; Name: robotic laparoscopic sacrocolpopexy; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Laparoscopic Sacral Colpopexy; Assigned to Arm(s): 1
D: Arm Label: Laparoscopic Abdominal Sacrocolpopexy (LASC); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard laparoscopic abdominal sacrocolpopexy | Arm Label: Robotic Assisted Laparoscopic (RASC); Type: EXPERIMENTAL; Interventions: Procedure: Robotic assisted laparoscopic abdominal sacrocolpopexy | Intervention Type: PROCEDURE; Name: Robotic assisted laparoscopic abdominal sacrocolpopexy; Assigned to Arm(s): Robotic Assisted Laparoscopic (RASC) | Intervention Type: PROCEDURE; Name: Standard laparoscopic abdominal sacrocolpopexy; Assigned to Arm(s): Laparoscopic Abdominal Sacrocolpopexy (LASC)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-term Effectiveness of Abdominal Sacrocolpopexy for the Treatment of Pelvic Organ Prolapse: The Extended Colpopexy and Urinary Reduction Efforts (E-CARE) Study
Brief Summary: The Colpopexy and Urinary Reduction Effort (CARE) trial is a research study designed to evaluate whether the addition of a second surgical procedure in addition to a procedure for female pelvic organ prolapse (POP) affects the rates of urinary incontinence. This study will follow women in the CARE study for 10 years from the time of the surgery to compare success and complication rates in the two groups. Recruitment into this study is open only to women that already participated in CARE. Recruitment into CARE is closed.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: retropubic mid-urethral sling (TVT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transobturator mid-urethral sling (TVT-O and the Monarc) | Intervention Type: PROCEDURE; Name: retropubic mid-urethral sling (TVT); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: transobturator mid-urethral sling (TVT-O and the Monarc); Assigned to Arm(s): 2
B: Arm Label: Burch; Type: OTHER; Interventions: Procedure: Burch Modified Tanagho | Arm Label: Sling; Type: OTHER; Interventions: Procedure: Autologous Fascia Sling | Intervention Type: PROCEDURE; Name: Burch Modified Tanagho; Assigned to Arm(s): Burch | Intervention Type: PROCEDURE; Name: Autologous Fascia Sling; Assigned to Arm(s): Sling
C: Arm Label: Abdominal Sacral Colpopexy with no Burch colposuspension; Type: N/A; Interventions: N/A | Arm Label: Abdominal Sacral Colpopexy with Burch Colposuspension; Type: N/A; Interventions: N/A
D: Arm Label: Abdominal Sacral Colpopexy with no Burch colposuspension; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Abdominal Sacral Colpopexy with Burch Colposuspension; Type: EXPERIMENTAL; Interventions: Procedure: Burch urethropexy at time of sacrocolpopexy | Intervention Type: PROCEDURE; Name: Burch urethropexy at time of sacrocolpopexy; Assigned to Arm(s): Abdominal Sacral Colpopexy with Burch Colposuspension

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International, Randomized, Multicenter, Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of at Least 104 Weeks: 1. Double-Blinded Safety, Tolerability, and Efficacy of Betaseron/ Betaferon 250 µg (8 MIU) and Betaseron/-Betaferon 500 µg (16 MIU), Both Given Subcutaneously Every Other Day, and 2. Rater-Blinded Safety, Tolerability, and Efficacy of Betaseron/-Betaferon s.c. Every Other Day With Copaxone 20 mg s.c. Once Daily.
Brief Summary: The purpose of this study is to determine

* whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe, tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms
* whether treatment with Betaferon / Betaseron (interferon beta-1b) tolerable and more efficacious than treatment with Copaxone (Glatiramer Acetate) 20 mg


Options:
A: Arm Label: Glatiramer acetate; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer Acetate (DB), Drug: Glatiramer Acetate (OL) | Arm Label: Placebo (DB) to GA (OL); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Glatiramer Acetate (OL) | Intervention Type: DRUG; Name: Glatiramer Acetate (DB); Assigned to Arm(s): Glatiramer acetate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (DB) to GA (OL) | Intervention Type: DRUG; Name: Glatiramer Acetate (OL); Assigned to Arm(s): Glatiramer acetate, Placebo (DB) to GA (OL)
B: Arm Label: IFNB-1b 500 mcg; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Arm Label: IFNB-1b 250 mcg; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Arm Label: IFNB-1b 250 mcg*; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Intervention Type: DRUG; Name: Interferon beta-1b (Betaseron, BAY86-5046); Assigned to Arm(s): IFNB-1b 250 mcg | Intervention Type: DRUG; Name: Interferon beta-1b (Betaseron, BAY86-5046); Assigned to Arm(s): IFNB-1b 500 mcg | Intervention Type: DRUG; Name: Interferon beta-1b (Betaseron, BAY86-5046); Assigned to Arm(s): IFNB-1b 250 mcg*
C: Arm Label: Rebif®; Type: EXPERIMENTAL; Interventions: Drug: Rebif® | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone® | Intervention Type: DRUG; Name: Rebif®; Assigned to Arm(s): Rebif® | Intervention Type: DRUG; Name: Copaxone®; Assigned to Arm(s): Copaxone®
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Copaxone; Assigned to Arm(s): Arm 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International, Randomized, Multicenter, Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of at Least 104 Weeks: 1. Double-Blinded Safety, Tolerability, and Efficacy of Betaseron/ Betaferon 250 µg (8 MIU) and Betaseron/-Betaferon 500 µg (16 MIU), Both Given Subcutaneously Every Other Day, and 2. Rater-Blinded Safety, Tolerability, and Efficacy of Betaseron/-Betaferon s.c. Every Other Day With Copaxone 20 mg s.c. Once Daily.
Brief Summary: The purpose of this study is to determine

* whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe, tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms
* whether treatment with Betaferon / Betaseron (interferon beta-1b) tolerable and more efficacious than treatment with Copaxone (Glatiramer Acetate) 20 mg


Options:
A: Arm Label: Previously treated with alemtuzumab; Type: EXPERIMENTAL; Interventions: Biological: alemtuzumab | Arm Label: Previously treated with interferon beta-1a (Rebif®); Type: EXPERIMENTAL; Interventions: Biological: alemtuzumab | Intervention Type: BIOLOGICAL; Name: alemtuzumab; Assigned to Arm(s): Previously treated with alemtuzumab, Previously treated with interferon beta-1a (Rebif®)
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Copaxone; Assigned to Arm(s): Arm 3
C: Arm Label: Daclizumab High Yield Process 150 mg SC; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Interferon beta-1a Placebo | Arm Label: IFN β-1a 30 µg IM; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a, Drug: Daclizumab High Yield Process Placebo | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: DRUG; Name: Interferon beta-1a Placebo; Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): IFN β-1a 30 µg IM | Intervention Type: DRUG; Name: Daclizumab High Yield Process Placebo; Assigned to Arm(s): IFN β-1a 30 µg IM
D: Arm Label: Fingolimod; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Multiple Sclerosis Disease Modifying Treatments (MS DMTs); Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard MS DMTs | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod | Intervention Type: DRUG; Name: Standard MS DMTs; Assigned to Arm(s): Multiple Sclerosis Disease Modifying Treatments (MS DMTs)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International, Randomized, Multicenter, Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of at Least 104 Weeks: 1. Double-Blinded Safety, Tolerability, and Efficacy of Betaseron/ Betaferon 250 µg (8 MIU) and Betaseron/-Betaferon 500 µg (16 MIU), Both Given Subcutaneously Every Other Day, and 2. Rater-Blinded Safety, Tolerability, and Efficacy of Betaseron/-Betaferon s.c. Every Other Day With Copaxone 20 mg s.c. Once Daily.
Brief Summary: The purpose of this study is to determine

* whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe, tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms
* whether treatment with Betaferon / Betaseron (interferon beta-1b) tolerable and more efficacious than treatment with Copaxone (Glatiramer Acetate) 20 mg


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Copaxone; Assigned to Arm(s): Arm 3
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol | Intervention Type: DRUG; Name: Glatiramer acetate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Albuterol placebo; Assigned to Arm(s): 1
C: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2
D: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multinational, Clinical Trial to Evaluate the Efficacy and Safety of Ranolazine vs Placebo in Patients With Non-ST Segment Elevation Acute Coronary Syndromes
Brief Summary: MERLIN-TIMI 36 is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of ranolazine during acute and long-term treatment in approximately 5,500 patients with non-ST elevation acute coronary syndromes (ACS) treated with standard therapy. The primary efficacy endpoint in MERLIN-TIMI 36 is time to first occurrence of any element of the composite of cardiovascular death, myocardial infarction or recurrent ischemia in patients with non-ST elevation ACS receiving standard therapy. The study also evaluates the safety of long-term treatment with ranolazine compared to placebo.


Options:
A: Arm Label: Study Drug Ranexa, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: Ranolazine, Drug: Placebo | Arm Label: Placebo, Then Study Drug Ranexa(Ranolazine); Type: EXPERIMENTAL; Interventions: Drug: Ranolazine, Drug: Placebo | Intervention Type: DRUG; Name: Ranolazine; Assigned to Arm(s): Placebo, Then Study Drug Ranexa(Ranolazine), Study Drug Ranexa, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Then Study Drug Ranexa(Ranolazine), Study Drug Ranexa, Then Placebo
B: Arm Label: Ranolazine; Type: EXPERIMENTAL; Interventions: Drug: Ranolazine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ranolazine; Assigned to Arm(s): Ranolazine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ranolazine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ranolazine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Ranolazine; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes
Brief Summary: Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to pioglitazone in people with type 2 diabetes not at target blood glucose levels on either pioglitazone or rosiglitazone alone.


Options:
A: Arm Label: Vildagliptin 50 mg qd + pioglitazone 45 mg qd; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: pioglitazone | Arm Label: Vildagliptin 50 mg bid + pioglitazone 45 mg qd; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: pioglitazone | Arm Label: Vildagliptin placebo + pioglitazone 45 mg qd; Type: PLACEBO_COMPARATOR; Interventions: Drug: pioglitazone, Drug: Placebo | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin 50 mg bid + pioglitazone 45 mg qd, Vildagliptin 50 mg qd + pioglitazone 45 mg qd | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Vildagliptin 50 mg bid + pioglitazone 45 mg qd, Vildagliptin 50 mg qd + pioglitazone 45 mg qd, Vildagliptin placebo + pioglitazone 45 mg qd | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Vildagliptin placebo + pioglitazone 45 mg qd
B: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
D: Arm Label: Sitagliptin 100 mg/100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin (MK0431), Drug: Metformin - Rescue | Arm Label: Sitagliptin 200 mg/200 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin, Drug: Metformin - Rescue | Arm Label: Placebo/Sitagliptin 100 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin - Rescue | Arm Label: Placebo/Sitagliptin 200 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin - Rescue | Intervention Type: DRUG; Name: Sitagliptin (MK0431); Assigned to Arm(s): Sitagliptin 100 mg/100 mg | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin 200 mg/200 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Sitagliptin 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Sitagliptin 200 mg | Intervention Type: DRUG; Name: Metformin - Rescue; Assigned to Arm(s): Placebo/Sitagliptin 100 mg, Placebo/Sitagliptin 200 mg, Sitagliptin 100 mg/100 mg, Sitagliptin 200 mg/200 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes
Brief Summary: The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to metformin in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar.


Options:
A: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
B: Arm Label: liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): liraglutide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin
C: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin Comparator | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Metformin Comparator; Assigned to Arm(s): Metformin
D: Arm Label: Metformin alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Glargine followed by Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Glargine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Liraglutide + Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Liraglutide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glargine followed by Metformin, Liraglutide + Metformin, Metformin alone | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide + Metformin | Intervention Type: DRUG; Name: Glargine; Assigned to Arm(s): Glargine followed by Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C